CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Belgium

  • ID: 4530772
  • Report
  • Region: Belgium
  • 131 pages
  • GlobalData
1 of 3
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Belgium

Summary

Belgium is one of the largest & mature healthcare markets, with a strong focus on pharmaceutical exports. It is also a major clinical trials hub in the European Union (EU). It spends approximately 10.4% of its GDP on healthcare. The value of the Belgian pharmaceutical market declined from over $7.5 billion in 2009 to around $6.9 billion in 2016, at a negative compound annual growth rate (CAGR) of about 2%. However, the value of the pharmaceutical market in terms of Euros increased from around €5.8 billion to €6.2 billion at a CAGR of 1%. This difference was due to the declining exchange rate of the Euro versus the US Dollar. The Belgian medical device market was valued at more than $2 billion in 2010, which increased to over $2.6 billion in 2017. Of these, the main segments were cardiovascular devices, ophthalmic devices, orthopedic devices, in vitro diagnostics and hospital supplies. The increasing elderly population and high investment in R&D expenditure are expected to drive the growth of the pharmaceutical market. However, generic substitution and high taxes act as a major barrier for the pharmaceutical market.The generics market generated around $880m in 2010, which increased to just over $995m in 2015.The OTC market generated upwards of $790m in 2012, which increased to over $1 billion in 2016.

Individually, people in Belgium spend around $4,800 per capita on healthcare. The average life expectancy was just over 78 years for men and more than 83 years for women in 2015, which is close to the Organization for Economic Co-operation and Development (OECD) average.In 2015, Belgium had the third highest volume of antibiotic consumption per capita among EU countries.The National Institute for Health and Disability Insurance launched public awareness campaigns and organized feedback to doctors to reduce the overuse of antibiotics.

The report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Belgium", provides information on the healthcare, regulatory, and reimbursement landscape in Belgium, and includes:
  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Pfizer, Sanofi, Leo Pharma, UCB Pharma and Ablynx) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Essilor, Zimmer Biomet, AGFA and IBA)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of Belgium
  • Porter’s five forces analysis for pharmaceutical and medical devices market of Belgium
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Belgian healthcare market
Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Belgium, and includes:
  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Pfizer, Sanofi, Leo Pharma, UCB Pharma and Ablynx) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Essilor, Zimmer Biomet, AGFA and IBA)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of Belgium
  • Porter’s five forces analysis for pharmaceutical and medical devices market of Belgium
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Belgian healthcare market.
Reasons to buy

This report will enhance your decision-making capability by allowing you to:
  • Develop business strategies by understanding the trends shaping and driving the Belgian healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
  • Identify, understand, and capitalize on the opportunities and challenges in the Belgian healthcare market.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
  • Executive Summary
  • Overview of Pharmaceutical Market
  • Overview of Medical Device Market
  • Deals Analysis
  • Porter’s Five Forces Model
  • Market Access
  • Country Healthcare Landscape
  • Opportunities and Challenges
  • Appendix
List of Tables
Table 1: Pharmaceutical Market, Belgium, Sales of Patented Drug Products by Major Therapeutic Class ($m), 2015
Table 2: Medical Device Market, Belgium, Revenue by Segment ($m), 2017
Table 3: Cardiovascular Devices Market, Belgium, Revenue ($m) and Market Share (%) of Major Companies, 2017
Table 4: Ophthalmic Devices Market, Belgium, Revenue ($m) and Market Share (%) of Major Companies, 2015
Table 5: Orthopedic Devices Market, Belgium, Revenue ($m) and Market Share (%) of Major Companies, 2016
Table 6: IVD Market, Belgium, Revenue ($m) and Market Share (%) of Major Companies, 2016
Table 7: Hospital Supplies Market, Belgium, Revenue ($m) and Market Share (%) of Major Companies, 2014
Table 8: Types of Reimbursement Claims, Belgium, 2017
Table 9: Reimbursement Categories, Belgium, 2017
Table 10: Co-payments, Belgium, 2017
Table 11: Market Authorization Fees, 2018, Belgium
Table 12: Patent Fees, Belgium, 2017
Table 13: Provisions for the advertisement of medicines for human use, Belgium, 2017
Table 14: Pharmacy Licensing Requirements, Belgium, 2017
Table 15: Primary Packaging Labeling Information, Belgium, 2017
Table 16: Blister Packaging Labeling Information, Belgium, 2017
Table 16: Small Packaging Labeling Information, Belgium, 2017
Table 17: Trade Fairs, Belgium, 2017

List of Figures
Figure 1: Pharmaceutical Market, Belgium, Revenue ($bn), 2010-2017
Figure 2: Medical Device Market, Belgium, Revenue ($bn), 2010-2017
Figure 3: Country Profile, Belgium, 2018
Figure 4: Pharmaceutical Market, Belgium, Revenue ($bn), 2010-2017
Figure 5: Pharmaceutical Market, Belgium, Revenue Forecast ($bn), 2018-2022
Figure 6: Pharmaceutical Exports ($bn), Belgium, 2010-2017
Figure 7: Top Export Partners, Belgium, 2016
Figure 8: Pharmaceutical Imports ($bn), Belgium, 2010-2017
Figure 9: Top Import Partners, Belgium, 2016
Figure 10: Pharmaceutical Market, Belgium, Major therapeutic groups based on sales ($m), 2015
Figure 11: Pharmaceutical Market, Belgium, Major Players
Figure 12: Medical Device Market, Belgium, Revenue ($bn), 2010-2017
Figure 13: Medical Device Market, Belgium, Revenue Forecast ($bn), 2018-2022
Figure 14: Medical Device Market, Belgium, Revenue by Segment ($m), 2017
Figure 15: Cardiovascular Devices Market, Belgium, Revenue ($m), 2010-2017
Figure 16: Cardiovascular Devices Market, Belgium, Market Share of Major Players (%), 2015
Figure 17: Ophthalmic Devices Market, Belgium, Revenue ($m), 2010-2017
Figure 18: Ophthalmic Devices Market, Belgium, Market Share of Major Players (%), 2017
Figure 19: Orthopedic Devices Market, Belgium, Revenue ($m), 2010-2017
Figure 20: Orthopedic Devices Market, Belgium, Market Share of Major Players (%), 2016
Figure 21: IVD Market, Belgium, Revenue ($m), 2010-2017
Figure 22: IVD Market, Belgium, Market Share of Major Companies (%), 2017
Figure 23: Hospital Supplies Market, Belgium, Revenue ($m), 2010-2017
Figure 24: Hospital Supplies Market, Belgium, Market Share of Major Companies (%), 2017
Figure 25: Diagnostic Market, Belgium, Revenue ($bn), 2010-2017
Figure 26: Diagnostic Market, Belgium, Revenue ($bn), 2018-2022
Figure 27: Medical Device Market, Belgium, Revenue ($bn) of Major Companies, 2016
Figure 28: Deal Value and Deal Count, Pharmaceutical Market, Belgium, 2017-2018
Figure 29: Deal Value and Deal Count Quarterly, Pharmaceutical Market, Belgium, 2017-2018
Figure 30:Deal Value and Deal Count Sub-Types, Pharmaceutical Market, Belgium, 2017-2018
Figure 31: Top 5 therapy area by deal value, Pharmaceutical Market, Belgium, 2017-2018
Figure 32: Top 5 therapy area by deal number, Pharmaceutical Market, Belgium, 2017-2018
Figure 33: VF deals by therapy area, Pharmaceutical Market, Belgium, 2017-2018 (By value and by number)
Figure 34: M&A deals by therapy area, Pharmaceutical Market, Belgium, 2017-2018 (By value and by number)
Figure 35: PE deals by therapy area, Pharmaceutical Market Belgium, 2017-2018 (By value and by number)
Figure 36:Medical Device Market Deals (by deal value, $m), Belgium, 2017-2018
Figure 37:Medical Device Market Deals (by deal count), Belgium, 2017-2018
Figure 38: Medical Device Market Deals Share (by deal count), Belgium, 2017-2018
Figure 39: Medical Device Market Deals Share (by deal value), Belgium, 2017-2018
Figure 40: Medical Device, Belgium, Top Therapy Area by Deal Value, 2017-2018
Figure 41: Medical Devices, Belgium, Top Therapy Area by Deal Number, 2017-2018
Figure 42: Medical Devices, Belgium, M&A Deals by Therapy Area, 2017-2018
Figure 43: Medical Devices, Belgium, VF Deals by Therapy Area, 2017-2018
Figure 44: Medical Devices, Belgium, PE Deals by Therapy Area, 2017-2018
Figure 45: NIHDI Organization Structure, Belgium, 2015
Figure 46: Reimbursement Process, Belgium, 2017
Figure 47: Out-of-Pocket Expenditure (% of total expenditure on health), Belgium, 2010-2017
Figure 48: Annual Rate of Change (%), Health Price Index, Belgium, 2010-2017
Figure 49: Federal Agency for Medicines and Health Products, Organization Chart, Belgium, 2017
Figure 50: Centralized Procedure, Belgium, 2017
Figure 51: Decentralized Procedure, Belgium, 2017
Figure 52: Mutual Recognition Procedure, Belgium, 2017
Figure 53: Conformity Assessment of Class I Medical Devices, EU, 2017
Figure 54: Conformity Assessment of Class IIa Medical Devices, EU, 2017
Figure 55: Conformity Assessment of Class IIb Medical Devices, EU, 2017
Figure 56: Conformity Assessment of Class III Medical Devices, EU, 2017
Figure 57: European Patent Approval Process, EU, 2017
Figure 58: Unitary Patent Approval Process, EU, 2017
Figure 59: Trademark Approval Process, Belgium, 2018
Figure 60: Clinical Trial Approval Process, Belgium, 2017
Figure 61: Number of Hospitals, Belgium, 2010-2017
Figure 62: Diagnostic Equipment (per million population), Belgium,2010-2017
Figure 63: Hospital Beds (per 100,000 population), Belgium, 2010-2017
Figure 64: Curative Care Hospital Beds (per 100,000 population), Belgium, 2010-2017
Figure 65: Psychiatric Hospital Beds (per 100,000 population), Belgium, 2010-2017
Figure 66: Life Expectancy, Belgium, 2010-2017
Figure 67: Immunization Rate (%), Belgium, 2010-2017
Figure 68: PM2.5 (µg per m3), Belgium, 2010-2017
Figure 69: CO2 Emissions (million tons), Belgium, 2010-2017
Figure 70: Physicians (per 1,000 population), Belgium, 2010-2017
Figure 71: Dentists (per 1,000 population), Belgium, 2010-2017
Figure 72: Nurses (per 1,000 population), Belgium, 2010-2017
Figure 73: Pharmacists (per 1,000 population), Belgium, 2010-2017
Figure 74: Major Causes of Mortality (number of deaths), Belgium, 2014
Figure 75: Major Causes of Male Mortality (number of deaths), Belgium, 2014
Figure 76: Major Causes of Female Mortality (number of deaths), Belgium, 2014
Figure 77: Disability-Adjusted Life Years by Major Disease (‘000), Belgium, 2015
Figure 78: Healthcare Expenditure as Percentage of GDP (%), Belgium, 2010-2017
Figure 79: Public-Private Share (%), Belgium, 2010-2017
Figure 80: Major Components of Healthcare Spending (%), Belgium, 2015
Figure 81:Spending in Pharmaceutical and Healthcare R&D ($bn), Belgium, 2010-2015
Figure 82: Opportunities and Challenges
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll